Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis
- PMID: 21030602
- DOI: 10.1158/1055-9965.EPI-10-0832
Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis
Abstract
Background: Body mass index (BMI) is a risk factor for endometrial cancer. We quantified the risk and investigated whether the association differed by use of hormone replacement therapy (HRT), menopausal status, and histologic type.
Methods: We searched MEDLINE and EMBASE (1966 to December 2009) to identify prospective studies of BMI and incident endometrial cancer. We did random-effects meta-analyses, meta-regressions, and generalized least square regressions for trend estimations assuming linear, and piecewise linear, relationships.
Results: Twenty-four studies (17,710 cases) were analyzed; 9 studies contributed to analyses by HRT, menopausal status, or histologic type, all published since 2003. In the linear model, the overall risk ratio (RR) per 5 kg/m(2) increase in BMI was 1.60 (95% CI, 1.52-1.68), P < 0.0001. In the piecewise model, RRs compared with a normal BMI were 1.22 (1.19-1.24), 2.09 (1.94-2.26), 4.36 (3.75-5.10), and 9.11 (7.26-11.51) for BMIs of 27, 32, 37, and 42 kg/m(2), respectively. The association was stronger in never HRT users than in ever users: RRs were 1.90 (1.57-2.31) and 1.18 (95% CI, 1.06-1.31) with P for interaction = 0.003. In the piecewise model, the RR in never users was 20.70 (8.28-51.84) at BMI 42 kg/m(2), compared with never users at normal BMI. The association was not affected by menopausal status (P = 0.34) or histologic type (P = 0.26).
Conclusions: HRT use modifies the BMI-endometrial cancer risk association.
Impact: These findings support the hypothesis that hyperestrogenia is an important mechanism underlying the BMI-endometrial cancer association, whilst the presence of residual risk in HRT users points to the role of additional systems.
©2010 AACR.
Similar articles
-
Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study.Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):723-30. doi: 10.1158/1055-9965.EPI-06-0675. Cancer Epidemiol Biomarkers Prev. 2007. PMID: 17416763
-
Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):73-9. doi: 10.1158/1055-9965.EPI-07-2567. Epub 2008 Jan 9. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18187388
-
What influence does hormone replacement therapy have on endometrial cancer risk?Nat Clin Pract Oncol. 2005 Nov;2(11):546-7. doi: 10.1038/ncponc0343. Nat Clin Pract Oncol. 2005. PMID: 16270092 No abstract available.
-
Hormone replacement therapy and cancer.Gynecol Endocrinol. 2001 Dec;15(6):453-65. Gynecol Endocrinol. 2001. PMID: 11826770 Review.
-
[Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer].Lakartidningen. 2001 Jan 31;98(5):418-21. Lakartidningen. 2001. PMID: 11229082 Review. Swedish.
Cited by
-
A new method that facilitates the diagnosis of endometrial cancer: the ratio of endometrial thickness to the full thickness of the uterine wall and subcutaneous adipose tissue measurements.Prz Menopauzalny. 2024 Mar;23(1):25-30. doi: 10.5114/pm.2024.136961. Epub 2024 Mar 28. Prz Menopauzalny. 2024. PMID: 38690066 Free PMC article.
-
Gene Expression Analysis for Uterine Cervix and Corpus Cancer Characterization.Genes (Basel). 2024 Feb 28;15(3):312. doi: 10.3390/genes15030312. Genes (Basel). 2024. PMID: 38540371 Free PMC article.
-
Predictive value of body mass index (BMI) and determination of optimum cut-off point in the diagnosis of endometrial hyperplasia in pre-menopausal women with abnormal uterine bleeding.Caspian J Intern Med. 2024 Winter;15(1):87-95. doi: 10.22088/cjim.15.1.9. Caspian J Intern Med. 2024. PMID: 38463922 Free PMC article.
-
Pulmonary metastasis of stage I, low-grade endometrioid carcinoma: two case reports and the literature review.Front Oncol. 2023 Oct 12;13:1266485. doi: 10.3389/fonc.2023.1266485. eCollection 2023. Front Oncol. 2023. PMID: 37901321 Free PMC article.
-
A Study on Survival Analysis Methods Using Neural Network to Prevent Cancers.Cancers (Basel). 2023 Sep 27;15(19):4757. doi: 10.3390/cancers15194757. Cancers (Basel). 2023. PMID: 37835451 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical